|
gptkbp:instanceOf
|
gptkb:Dragon
|
|
gptkbp:administeredBy
|
injection
|
|
gptkbp:antidote
|
antitoxin
|
|
gptkbp:approvedBy
|
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:CASNumber
|
93384-43-1 (Type A)
|
|
gptkbp:category
|
gptkb:protein
bacterial toxin
neuroparalytic agent
|
|
gptkbp:class
|
biological weapon
|
|
gptkbp:discoveredBy
|
gptkb:Emile_van_Ermengem
|
|
gptkbp:discoveredIn
|
1895
|
|
gptkbp:effect
|
3-6 months
causes muscle paralysis
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Botulinum toxin
|
|
gptkbp:LD50
|
estimated 1 ng/kg intravenously
estimated 3 ng/kg inhaled
estimated 70 μg for average adult
|
|
gptkbp:marketedAs
|
gptkb:Botox
gptkb:Myobloc
gptkb:Dysport
gptkb:Jeuveau
gptkb:Xeomin
|
|
gptkbp:mechanismOfAction
|
inhibits acetylcholine release
|
|
gptkbp:producedBy
|
gptkb:Clostridium_botulinum
|
|
gptkbp:regulates
|
gptkb:Centers_for_Disease_Control_and_Prevention
gptkb:World_Health_Organization
|
|
gptkbp:riskFactor
|
botulism
|
|
gptkbp:routeOfAdministration
|
intramuscular
subcutaneous
intradermal
|
|
gptkbp:sideEffect
|
respiratory problems
difficulty swallowing
muscle weakness
allergic reaction
dry mouth
flu-like symptoms
drooping eyelids
|
|
gptkbp:structure
|
gptkb:protein
|
|
gptkbp:toxicity
|
highly toxic
|
|
gptkbp:type
|
G
A
B
C
D
E
F
|
|
gptkbp:UNII
|
Q3ZBG6X2QY (Type A)
|
|
gptkbp:usedFor
|
treatment of cervical dystonia
treatment of chronic migraine
treatment of muscle spasms
treatment of strabismus
cosmetic treatment
treatment of hyperhidrosis
|
|
gptkbp:bfsParent
|
gptkb:Biological_Weapons
|
|
gptkbp:bfsLayer
|
5
|